SFM
MDGL icon

Sphera Funds Management’s Madrigal Pharmaceuticals MDGL Stock Holding History

Sphera Funds Management’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-2,857
Closed -$524K – 128
2013
Q4 		$524K Buy
+2,857
New +$523K 0.15% 91

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Sphera Funds Management's MDGL Position: Q2 2026 in Review

Sphera Funds Management increased its Madrigal Pharmaceuticals (MDGL) stake by 93% in Q2 2026, buying an estimated $4.29M and bringing the position to 17,419 shares worth $9.35M. The position accounts for 1.22% of the portfolio, ranked #20.

Sphera Funds Management first reported a position in MDGL in Q1 2023 and has held it in 7 quarters since. 414 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • Sphera Funds Management held 17,419 shares of Madrigal Pharmaceuticals worth $9.35M as of Q2 2026.
  • Sphera Funds Management bought 8,379 Madrigal Pharmaceuticals shares in Q2 2026, an estimated $4.29M.
  • Madrigal Pharmaceuticals made up 1.22% of Sphera Funds Management's portfolio in Q2 2026, its #20 holding.
  • Sphera Funds Management first reported a position in Madrigal Pharmaceuticals in Q1 2023 and has held it in 7 quarters since.
  • 414 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Sphera Funds Management's 13F filing for Q2 2026, filed 14 Aug 2026.